|
|
||||||||
Donner Laboratory, University of California, Berkeley, California
Oak Ridge Associated Universities, Oak Ridge, Tennessee
Correspondence: For reprints contact: H. S. Winchell, Donner Laboratory and Donner Pavilion, University of California Berkeley, Berkeley, Calif. 94720.
ABSTRACT
The 67Ga-citrate was administered to 18 patients with a variety of malignant neoplasias. In 11 patients definite abnormal localization of the 67Ga in tumors occurred. Positive results were obtained in all five patients with lymphoma. The Anger whole-body counter, scintillation camera and tomographic scanner all generally showed good resolution of the tumor from surrounding tissue. However, the tomographic scanner had the advantage of also indicating the depth of tumor within the body. Generally when the 67Ga localized in tumors, not all of the tumor mass within the body of the patient showed such accumulation, suggesting that variations in metabolic activity or vascular perfusion of the tumor were responsible for the localization.
Gallium-67 administered as the citrate can localize in a variety of non-neoplastic soft tissues. In the present study 67Ga was noted in gynecomastia and variably in the pelvis of female patients. In several cases, the marked localization of the 67Ga within the body appeared to give information concerning the presence of a tumor which could not be obtained by use of other clinical detection methods. These results suggest that chelated carrier-free metals, such as 67Ga, will prove clinically useful in evaluating the presence and distribution of malignant neoplastic tissue in human subjects.
FOOTNOTES
* On sabbatical leave from University of Sydney, Sydney, Australia.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |